{"id":22596,"date":"2023-10-09T07:18:00","date_gmt":"2023-10-09T07:18:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4232593_CN32593_0"},"modified":"2023-10-09T07:18:00","modified_gmt":"2023-10-09T07:18:00","slug":"aacr-ovarian-cancer-conference-presentation","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=22596","title":{"rendered":"AACR OVARIAN CANCER CONFERENCE PRESENTATION"},"content":{"rendered":"<p><b>HIGHLIGHTS<\/b><\/p>\n<ul type=\"disc\">\n<li><i>Data from preclinical studies in ovarian cancer presented at premier international conference in <span class=\"xn-location\">Boston<\/span>, USA.&nbsp;<\/i><\/li>\n<li><i>Results indicate that&nbsp;Amplia&#8217;s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer<\/i><\/li>\n<li><i>Data from these studies support clinical study of&nbsp;narmafotinib in ovarian cancer \u2013 with plans now commencing with leading international cancer specialists<\/i><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">MELBOURNE, Australia<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Oct. 9, 2023<\/span><\/span> \/PRNewswire\/ &#8212; Amplia Therapeutics Limited (ASX: ATX), (&#8220;Amplia&#8221; or the &#8220;Company&#8221;) is pleased to announce that a poster, detailing a series of preclinical studies in ovarian cancer models, was presented at the <b>American Association for Cancer Research<\/b> <b>(AACR) Special Conference In Cancer Research: Ovarian Cancer <\/b>meeting, held in <span class=\"xn-location\">Boston<\/span>, <span class=\"xn-location\">USA<\/span> over the weekend. The poster describes research with narmafotinib (AMP945) conducted by the company&#8217;s collaborators at the <span class=\"xn-org\">University of California, San Diego<\/span> (UCSD), and was presented by lead researcher Prof <span class=\"xn-person\">Dwayne Stupack<\/span>.<\/p>\n<p>The data presented clearly demonstrates that narmafotinib is active in mouse models of chemotherapy-resistant ovarian cancer with improved tumour growth inhibition activity and tolerability compared to a PARP inhibitor (niraparib), the current standard-of-care agent for this chemotherapy-resistant patient population. Moreover, narmafotinib showed promising activity in a model where niraparib therapy is ineffective. These results build on previous research by Prof. Stupack and his collaborators showing that activity of the FAK enzyme is upregulated in chemotherapy-resistant ovarian cancer and that FAK inhibition resensitises the cancer to standard-of-care chemotherapy and immunotherapy as well.<\/p>\n<p><b>Lead researcher Prof <span class=\"xn-person\">Dwayne Stupack<\/span> stated: <\/b>&#8220;PARP inhibitors are now widely used in the treatment of high-grade serous ovarian cancer (HGSOC) and work well in a subset of patients with what&#8217;s known as homologous recombinant deficient (HRD) HGSOC \u2013 at least until drug resistance occurs.&nbsp; &nbsp;We have shown in our preclinical models that narmafotinib (AMP945) has better activity across the non-HRD disease, and importantly works in PARP inhibitor-resistant disease as well.&nbsp; Moreover, it appears to be very well tolerated, which is important for a drug that will be taken daily.&#8221;<\/p>\n<p>A copy of the presentation, entitled &#8216;<i>Maintenance therapy inhibition of ptk2 [FAK] yields decreased disease in preclinical models of HRP\/HRD models of recurrent HGSOC&#8217;<\/i> is available on the Company&#8217;s website <a href=\"https:\/\/www.ampliatx.com\/site\/Media\/aacr-ovarian-cancer-conference-presentation?ListPageUrl=https%3A%2F%2Fwww.ampliatx.com%3A443%2Fsite%2FMedia\" target=\"_blank\" rel=\"nofollow noopener\">here.<\/a><\/p>\n<p><b>Amplia CEO and MD, Dr <span class=\"xn-person\">Chris Burns<\/span> commented:<\/b> &#8220;The research results presented today by Prof. Stupack are extremely exciting and clearly demonstrate that our best-in-class FAK inhibitor narmafotinib has significant potential in the treatment of ovarian cancer. Given that over 1000 women in <span class=\"xn-location\">Australia<\/span> die each year of this disease, there is a clear need for better treatment, and plans are now underway to work with local and international ovarian cancer specialists to initiate a clinical trial of narmafotinib in ovarian cancer patients.<\/p>\n<p>&#8220;The clinical potential of FAK inhibition in ovarian cancer was demonstrated earlier this year with the first-generation FAK inhibitor defactinib showing promising activity in patients with low-grade serous ovarian cancer. Our preclinical results in models of high-grade disease, which represents over 90% of all ovarian cancer patients, further underscore the potential role of FAK inhibitors in treatment of this disease.&#8221;<\/p>\n<p>This ASX announcement was approved and authorised for release by the Board.<\/p>\n<p><b>About Amplia Therapeutics Limited<\/b><\/p>\n<p>Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit <a href=\"http:\/\/www.ampliatx.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.ampliatx.com<\/a> and follow Amplia on <a href=\"https:\/\/twitter.com\/ampliatx\" target=\"_blank\" rel=\"nofollow noopener\">Twitter<\/a> (@ampliatx), <a href=\"https:\/\/www.threads.net\/@ampliatx\" target=\"_blank\" rel=\"nofollow noopener\">Threads<\/a> (@ampliatx) and <a href=\"https:\/\/www.linkedin.com\/company\/amplia-therapeutics\/\" target=\"_blank\" rel=\"nofollow noopener\">LinkedIn<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA.&nbsp; Results indicate that&nbsp;Amplia&#8217;s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer Data from these studies support clinical study of&nbsp;narmafotinib in ovarian cancer \u2013 with plans now commencing with leading international [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-22596","post","type-post","status-publish","format-standard","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AACR OVARIAN CANCER CONFERENCE PRESENTATION - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=22596\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AACR OVARIAN CANCER CONFERENCE PRESENTATION - My Blog\" \/>\n<meta property=\"og:description\" content=\"HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA.&nbsp; Results indicate that&nbsp;Amplia&#8217;s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer Data from these studies support clinical study of&nbsp;narmafotinib in ovarian cancer \u2013 with plans now commencing with leading international [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=22596\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-09T07:18:00+00:00\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"AACR OVARIAN CANCER CONFERENCE PRESENTATION\",\"datePublished\":\"2023-10-09T07:18:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596\"},\"wordCount\":604,\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596\",\"name\":\"AACR OVARIAN CANCER CONFERENCE PRESENTATION - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"datePublished\":\"2023-10-09T07:18:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=22596#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AACR OVARIAN CANCER CONFERENCE PRESENTATION\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AACR OVARIAN CANCER CONFERENCE PRESENTATION - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=22596","og_locale":"en_US","og_type":"article","og_title":"AACR OVARIAN CANCER CONFERENCE PRESENTATION - My Blog","og_description":"HIGHLIGHTS Data from preclinical studies in ovarian cancer presented at premier international conference in Boston, USA.&nbsp; Results indicate that&nbsp;Amplia&#8217;s proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade serous ovarian cancer Data from these studies support clinical study of&nbsp;narmafotinib in ovarian cancer \u2013 with plans now commencing with leading international [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=22596","og_site_name":"My Blog","article_published_time":"2023-10-09T07:18:00+00:00","author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=22596#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=22596"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"AACR OVARIAN CANCER CONFERENCE PRESENTATION","datePublished":"2023-10-09T07:18:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=22596"},"wordCount":604,"articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=22596","url":"https:\/\/transmediavictoria.net.au\/?p=22596","name":"AACR OVARIAN CANCER CONFERENCE PRESENTATION - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"datePublished":"2023-10-09T07:18:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=22596#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=22596"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=22596#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"AACR OVARIAN CANCER CONFERENCE PRESENTATION"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/22596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=22596"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/22596\/revisions"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=22596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=22596"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=22596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}